Intraarticular Application of Opioids versus Glucocorticoids versus Placebo in Gonarthritis

Recruitment status	Prospectively registered
No longer recruiting	☐ Protocol
Overall study status	Statistical analysis plan
Completed	Results
Condition category	Individual participant data
Musculoskeletal Diseases	Record updated in last year
	Overall study status Completed Condition category

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Joachim Sieper

Contact details

Charité Campus Benjamin Franklin Dept of Rheumatology Hindenburgdamm 30 Berlin Germany 12200 +49 (0)3084454414 joachim.sieper@charite.de

Additional identifiers

Protocol serial number N/A

Study information

Scientific Title

Study objectives

Assessment of efficacy and safety of intraarticular applicated Morphine versus Dexamethasone versus Placebo in gonarthritis in inflammatory rheumatic disease

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Gonarthritis in inflammatory rheumatic disease

Interventions

Single injection of Morphine 3 mg or Dexamethasone 4 mg or Placebo during needle arthroscopy. Rearthroscopy after 7 days.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Morphine, Dexamethasone

Primary outcome(s)

Improvement of VAS pain of at least 20 mm on a 0-100 scale.

Key secondary outcome(s))

Impovement of a numeric pain scale, sleep quality, global daily activity, knee mobility with Lysholm and Gilquist Score, Western Ontario McMaster Universities Osteoarthritis (WOMAC) index, relief of pain on a numeric scale from 0-3.

Completion date

01/01/2006

Eligibility

Key inclusion criteria

- 1. Age 19-70
- 2. Gonarthritis with sonographically evident effusion in inflammatory rheumatic disease
- 3. Visual analogue score (VAS) pain >30 mm
- 4. Body weight 50-90 kg
- 5. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

- 1. Pregnancy, lactation
- 2. Severe or opportunistic infection, infection of the knee
- 3. Malignant diseases
- 4. Any other severe diseases
- 5. Platelets <100/nl, Quick <50
- 6. Significant findings during clinical examination
- 7. Participation in a clinical trial within 30 days before inclusion
- 8. Abuse of hard drugs, benzodiacepines, analgesics, alcohol
- 9. Therapy with anticoagulants

Date of first enrolment

01/01/2004

Date of final enrolment

01/01/2006

Locations

Countries of recruitment

Germany

Study participating centre Charité Campus Benjamin Franklin

Berlin Germany 12200

Sponsor information

Organisation

Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany)

ROR

https://ror.org/001w7jn25

Funder(s)

Funder type

Research organisation

Funder Name

German Research Foundation (Deutsche Forschungsgemeinschaft) KFO 100

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration